Jaguar Health expands out-licensing deal for schizophrenia drug candidate with Magdalena Biosciences.

Jaguar Health announces expansion of out-licensing deal with Magdalena Biosciences, a joint venture with Filament Health, for a botanical drug candidate to treat schizophrenia. The drug demonstrates antipsychotic activity and a unique mechanism of action. Jaguar will receive a percentage of milestone payments and increasing royalties upon commercialization into the $8.06bn US schizophrenia market by 2030.